Cui X, Liang Z. Association between metabolic dysfunction-associated steatotic liver disease, vitamin D3, and diabetic gastric motility disorders in type 2 diabetes mellitus. World J Hepatol 2025; 17(11): 112060 [DOI: 10.4254/wjh.v17.i11.112060]
Corresponding Author of This Article
Xu Cui, PhD, FRCS (Gen Surg), Department of Pediatric Surgery, Fujian Children’s Hospital (Fujian Branch of Shanghai Children’s Medical Center), No. 18 Daoshan Road, Fuzhou 350005, Fujian Province, China. 16802937@qq.com
Research Domain of This Article
Nutrition & Dietetics
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Nov 27, 2025 (publication date) through Dec 4, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Cui X, Liang Z. Association between metabolic dysfunction-associated steatotic liver disease, vitamin D3, and diabetic gastric motility disorders in type 2 diabetes mellitus. World J Hepatol 2025; 17(11): 112060 [DOI: 10.4254/wjh.v17.i11.112060]
World J Hepatol. Nov 27, 2025; 17(11): 112060 Published online Nov 27, 2025. doi: 10.4254/wjh.v17.i11.112060
Association between metabolic dysfunction-associated steatotic liver disease, vitamin D3, and diabetic gastric motility disorders in type 2 diabetes mellitus
Xu Cui, Zheng Liang
Xu Cui, Department of Pediatric Surgery, Fujian Children’s Hospital (Fujian Branch of Shanghai Children’s Medical Center), Fuzhou 350005, Fujian Province, China
Xu Cui, College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fuzhou 350112, Fujian Province, China
Zheng Liang, Institute of Transformation Studies, Fujian Children’s Hospital (Fujian Branch of Shanghai Children’s Medical Center), Fuzhou 350005, Fujian Province, China
Co-first authors: Xu Cui and Zheng Liang.
Author contributions: Cui X participated in the conception of research ideas, literature retrieval and analysis, drafted and revised the core viewpoints of the letter (including questioning of exclusion criteria, elaboration of relevant mechanisms, and analysis of the association between vitamin D3 and metabolic pathways); Zheng L participated in the screening and argumentation of key literatures, conducted supplementary revisions on the mechanism of action of vitamin D3 in metabolism-related diseases and the section of research design suggestions, and assisted in refining the logical flow and academic expression of the letter, they contributed equally to this manuscript and are co-first authors.
Supported by Fujian Provincial Science and Technology Innovation Joint Fund Project, No. 2024Y9555; Youth Research Project of the Science and Technology Plan of Fujian Provincial Health Commission, No. 2024QNB005; Fujian Provincial Natural Science Foundation Project, No. 2024J011124; and Fujian Provincial Medical Project for Creating Dual High-Quality Development (High Level and High Standard), No. ETK2025004.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xu Cui, PhD, FRCS (Gen Surg), Department of Pediatric Surgery, Fujian Children’s Hospital (Fujian Branch of Shanghai Children’s Medical Center), No. 18 Daoshan Road, Fuzhou 350005, Fujian Province, China. 16802937@qq.com
Received: July 17, 2025 Revised: August 18, 2025 Accepted: October 17, 2025 Published online: November 27, 2025 Processing time: 132 Days and 23.8 Hours
Abstract
This letter comments on a study linking metabolic dysfunction-associated steatotic liver disease (MASLD), vitamin D3, and severe gastric autonomic neuropathy (diabetic gastric motility disorders) in type 2 diabetes mellitus (T2DM). We question the necessity of excluding patients with severe cataract (unable to complete fundus exams), as the focus on T2DM-MASLD correlation may render other T2DM complications less relevant. We emphasize vitamin D3’s multifaceted relevance: It associates with T2DM (high-dose supplementation reduces onset risk), MASLD (serum levels predict risk), smooth muscle function, immunity, and T2DM-related fractures via advanced glycation end products. We propose correlating MASLD severity with vitamin D3 levels and diabetic gastric motility disorders in validation analyses (e.g., correlation, area under the curve) to refine factor analysis. Additionally, based on the authors’ note of vitamin D3-tryptophan metabolism links, we call for deeper integration of metabolic pathways to clarify vitamin D3’s role in smooth muscle electrophysiology, leveraging the team’s prior research insights.
Core Tip: This letter discusses a study linking metabolic dysfunction-associated steatotic liver disease, vitamin D3, and diabetic gastric motility disorders in type 2 diabetes mellitus, suggests refining exclusion criteria, highlights vitamin D3’s roles in metabolism and smooth muscle function, and proposes correlating metabolic dysfunction-associated steatotic liver disease severity with vitamin D3 and motility disorders, while anticipating deeper exploration of vitamin D3’s physiological functions via metabolic pathways.
